Literature DB >> 21607625

RNA interference and ischemic injury.

Min Liu1, Jin Sun, Wen Wang, Jia-Wang Ding, Shu-Guo Li, Shubash Adhikari, Li Li, Jun Yang.   

Abstract

In the early period of 21st century, RNA interference (RNAi) had emerged as one of the most important discoveries. This highly conserved endogenous gene silencing mechanism has been largely exploited as a powerful tool to determine biological functions of each gene. Both direct introduction of chemically synthesized small interference RNA (siRNA) and a plasmid or viral vectors encoding for siRNA can allow especially stable RNA knockdown. Recently, it has been widely used in the production of therapeutic drugs against hepatitis or immuno-deficiency viruses in human beings. Here, we provide a brief overview of the RNAi mechanism and the technology of RNAi on ischemic injury.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21607625     DOI: 10.1007/s11033-011-0775-5

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  53 in total

Review 1.  RNA interference.

Authors:  Gregory J Hannon
Journal:  Nature       Date:  2002-07-11       Impact factor: 49.962

2.  Quelling: transient inactivation of gene expression in Neurospora crassa by transformation with homologous sequences.

Authors:  N Romano; G Macino
Journal:  Mol Microbiol       Date:  1992-11       Impact factor: 3.501

3.  Highly specific and accurate selection of siRNAs for high-throughput functional assays.

Authors:  Javier Santoyo; Juan M Vaquerizas; Joaquín Dopazo
Journal:  Bioinformatics       Date:  2004-12-10       Impact factor: 6.937

Review 4.  Strategies for silencing human disease using RNA interference.

Authors:  Daniel H Kim; John J Rossi
Journal:  Nat Rev Genet       Date:  2007-03       Impact factor: 53.242

5.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.

Authors:  A Fire; S Xu; M K Montgomery; S A Kostas; S E Driver; C C Mello
Journal:  Nature       Date:  1998-02-19       Impact factor: 49.962

6.  A genetic link between co-suppression and RNA interference in C. elegans.

Authors:  R F Ketting; R H Plasterk
Journal:  Nature       Date:  2000-03-16       Impact factor: 49.962

7.  Protection of renal ischemia injury using combination gene silencing of complement 3 and caspase 3 genes.

Authors:  Xiufen Zheng; Xusheng Zhang; Hongtao Sun; Biao Feng; Mu Li; Gang Chen; Costin Vladau; Dong Chen; Motohiko Suzuki; Lisa Min; Weihua Liu; Robert Zhong; Bertha Garcia; Anthony Jevnikar; Wei-Ping Min
Journal:  Transplantation       Date:  2006-12-27       Impact factor: 4.939

8.  par-1, a gene required for establishing polarity in C. elegans embryos, encodes a putative Ser/Thr kinase that is asymmetrically distributed.

Authors:  S Guo; K J Kemphues
Journal:  Cell       Date:  1995-05-19       Impact factor: 41.582

9.  Caspase-8 and caspase-3 small interfering RNA decreases ischemia/reperfusion injury to the liver in mice.

Authors:  Juan L Contreras; Mario Vilatoba; Christopher Eckstein; Guadalupe Bilbao; J Anthony Thompson; Devin E Eckhoff
Journal:  Surgery       Date:  2004-08       Impact factor: 3.982

10.  MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice.

Authors:  Angelika Bonauer; Guillaume Carmona; Masayoshi Iwasaki; Marina Mione; Masamichi Koyanagi; Ariane Fischer; Jana Burchfield; Henrik Fox; Carmen Doebele; Kisho Ohtani; Emmanouil Chavakis; Michael Potente; Marc Tjwa; Carmen Urbich; Andreas M Zeiher; Stefanie Dimmeler
Journal:  Science       Date:  2009-05-21       Impact factor: 47.728

View more
  1 in total

1.  Effects of AAV-mediated knockdown of nNOS and GPx-1 gene expression in rat hippocampus after traumatic brain injury.

Authors:  Deborah R Boone; Jeanna M Leek; Michael T Falduto; Karen E O Torres; Stacy L Sell; Margaret A Parsley; Jeremy C Cowart; Tatsuo Uchida; Maria-Adelaide Micci; Douglas S DeWitt; Donald S Prough; Helen L Hellmich
Journal:  PLoS One       Date:  2017-10-10       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.